Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | V654A |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | KIT V654A lies within the protein kinase domain (exon 13) of the Kit protein (UniProt.org). V654A has been described as a secondary drug resistance mutation (PMID: 17363509, PMID: 16751810), but has conflicting functional data, as in some studies, results in increased proliferation in cultured cells and in murine cells (corresponding to V653A), leads to increased proliferation and elevated Stat activation in the context of KIT V559del (corresponding to V558del in mouse) in culture (PMID: 33024275), is constitutively phosphorylated in culture (PMID: 27440273), but in another study is not transforming and does not result in constitutive activation (PMID: 17363509), and therefore, its effect on Kit protein function is unknown. |
Associated Drug Resistance | Y |
Category Variants Paths |
KIT mutant KIT exon13 KIT V654X KIT V654A |
Transcript | NM_000222.3 |
gDNA | chr4:g.54728092T>C |
cDNA | c.1961T>C |
Protein | p.V654A |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000222.3 | chr4:g.54728092T>C | c.1961T>C | p.V654A | RefSeq | GRCh38/hg38 |
XM_017008178 | chr4:g.54728092T>C | c.1961T>C | p.V654A | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54728092T>C | c.1961T>C | p.V654A | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54728092T>C | c.1961T>C | p.V654A | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54728092T>C | c.1961T>C | p.V654A | RefSeq | GRCh38/hg38 |
XM_017008178.1 | chr4:g.54728092T>C | c.1961T>C | p.V654A | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT V654A | Advanced Solid Tumor | sensitive | Axitinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT V654A in culture, and inhibited tumor growth in xenograft models (PMID: 31205508). | 31205508 |
KIT V654A | Advanced Solid Tumor | resistant | Imatinib | Preclinical | Actionable | In a preclinical study, cells expressing KIT V654A demonstrated resistance to Gleevec (imatinib) in culture (PMID: 16751810). | 16751810 |
KIT V654A | Advanced Solid Tumor | sensitive | Nintedanib | Preclinical - Cell culture | Actionable | In a preclinical study, Ofev (nintedanib) inhibited proliferation of transformed cells expressing KIT V654A in culture (PMID: 35194937). | 35194937 |
KIT V654A | Advanced Solid Tumor | sensitive | Ponatinib | Preclinical | Actionable | In a preclinical study, cells expressing KIT V654A demonstrated some sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608). | 25239608 |
KIT V654A | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT V654A in culture (PMID: 31205508). | 31205508 |
KIT V654A | Advanced Solid Tumor | sensitive | Sunitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT V654A in culture (PMID: 35194937). | 35194937 |
KIT V654A | gastrointestinal stromal tumor | predicted - resistant | Avapritinib | Phase I | Actionable | In a Phase I trial, patients with gastrointestinal stromal tumors harboring either KIT V654A or KIT T670I demonstrated decreased overall response rate (0%, 0/25 vs. 26%, 22/84) and increased progressive disease rate (72% vs 23%) compared to those without either KIT mutation when treated with Ayvakit (avapritinib) (PMID: 31270078; NCT02508532). | 31270078 |